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Abstract
Objective To systematically review longitudinal studies evaluating use
of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor
blockers (ARBs) and risk of pneumonia.
Design Systematic review and meta-analysis.
Data sourcesMedline through PubMed,Web of Science with conference
proceedings (inception to June 2011), and US Food and Drug
Administration website (June 2011). Systematic reviews and references
of retrieved articles were also searched.
Study selection Two reviewers independently selected randomised
controlled trials and cohort and case-control studies evaluating the use
of ACE inhibitors or ARBs and risk of pneumonia and retrieved
characteristics of the studies and data estimates.
Data synthesis The primary outcome was incidence of pneumonia and
the secondary outcome was pneumonia related mortality. Subgroup
analyses were carried according to baseline morbidities (stroke, heart
failure, and chronic kidney disease) and patients’ characteristics (Asian
and non-Asian). Pooled estimates of odds ratios and 95% confidence
intervals were derived by random effects meta-analysis. Adjusted
frequentist indirect comparisons between ACE inhibitors and ARBs were
estimated and combined with direct evidence whenever available.
Heterogeneity was assessed using the I2 test.
Results 37 eligible studies were included. ACE inhibitors were associated
with a significantly reduced risk of pneumonia compared with control
treatment (19 studies: odds ratio 0.66, 95% confidence interval 0.55 to
0.80; I2=79%) and ARBs (combined direct and indirect odds ratio estimate
0.69, 0.56 to 0.85). In patients with stroke, the risk of pneumonia was
also lower in those treated with ACE inhibitors compared with control
treatment (odds ratio 0.46, 0.34 to 0.62) and ARBs (0.42, 0.22 to 0.80).
ACE inhibitors were associated with a significantly reduced risk of
pneumonia among Asian patients (0.43, 0.34 to 0.54) compared with
non-Asian patients (0.82, 0.67 to 1.00; P<0.001). Compared with control
treatments, both ACE inhibitors (seven studies: odds ratio 0.73, 0.58 to
0.92; I2=51%) and ARBs (one randomised controlled trial: 0.63, 0.40 to
1.00) were associated with a decrease in pneumonia related mortality,
without differences between interventions.
Conclusions The best evidence available points towards a putative
protective role of ACE inhibitors but not ARBs in risk of pneumonia.
Patient populations that may benefit most are those with previous stroke
and Asian patients. ACE inhibitors were also associated with a decrease
in pneumonia related mortality, but the data lacked strength.
Introduction
Pneumonia represents an important clinical condition because
of its relatively high incidence (0.5% to 1.1% annually in the
United Kingdom) and associated morbidity and mortality.1 2
Susceptibility is higher among elderly people (≥65 years), those
with alcohol dependency, smokers, and patients with heart
failure, previous stroke, diabetes, chronic kidney disease, and
chronic lung disease.3-6 Pneumonia is a common reason for
hospital admission and a risk factor for prolonged hospital stay,
carrying a considerable financial burden on healthcare
resources.7 8
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Usage of some drugs has been shown to modulate the risk of
pneumonia. Acid suppressants can increase patients’
susceptibility to pneumonia, whereas statins may have a
protective role.9 10 Angiotensin converting enzyme (ACE)
inhibitors and angiotensin receptor blockers (ARBs) are often
used in patients with cardiovascular disease. ACE inhibitors are
known to have adverse effects on the respiratory system, in
particular an increased incidence of cough. Basic investigation
has shown that bradykinin and substance P sensitise the sensory
nerves of the airways and enhance the cough reflex,11-13 which
may have a protective role on the tracheobronchial tree.14 15
These mechanisms also improve swallowing by avoiding the
exposure of the respiratory tree to oropharynx secretions.11 14 16
Taken together, the pleiotropic effects of ACE inhibitors were
suggested to reduce the incidence of pneumonia, but available
clinical evidence lacks strength17-19 and published results have
been contradictory.20-22
We systematically reviewed and meta-analysed all studies
(experimental and observational) evaluating the use of ACE
inhibitors and incidence of pneumonia. Because the clinical
characteristics and risk factors of populations using ARBs are
similar to those of patients using ACE inhibitors, and therefore
studies evaluating these interventions share identical potential
clinical confounders, we also estimated the incidence of
pneumonia in studies evaluating ARBs. Moreover, patients
treated with ARBs are less likely to experience respiratory
adverse events,23 24 and therefore ARBs may have a protective
role.
Methods
The systematic review was carried out in accordance with the
meta-analysis of observational studies in epidemiology and
preferred reporting items for systematic reviews and
meta-analyses statements.25 26
Our primary outcome was the incidence of pneumonia. We
considered cases of pneumonia, lower respiratory tract
infections, and admissions to hospital due to lower respiratory
tract infections. Data were extracted irrespective of whether
they had been reported as predefined outcomes or as adverse
effects. If studies reported data for death from pneumonia only,
to avoid duplication we did not consider these cases for the
primary outcome. The secondary outcome was pneumonia
related mortality, defined as death directly related to this
condition or in-hospital death or mortality within 30 days after
onset of pneumonia.27 For both outcomes, we did not consider
undefined data or data on upper respiratory tract infections.
We considered randomised controlled parallel trials, cohort
studies, and case-control studies with ACE inhibitors or ARBs
as interventions and with predefined outcomes. Treatment arms
could compare ACE inhibitors and ARBs with each other or
with placebo or any other active drug. Cohort studies could be
based on populations in the community or those in institutions
or hospital and had to follow patients to determine pneumonia
outcomes.
In case-control studies, cases had to be defined as patients with
new onset pneumonia identified through clinical examination,
radiological methods, or database codes. Controls had to be
matched to cases, but without new onset pneumonia. For
pneumonia related mortality, we allowed case-control studies
with both cases and controls having pneumonia.
We allowed all participants, irrespective of baseline diseases
and risk factors.
Information sources and search method
We identified potentially eligible studies through an electronic
search of bibliographic databases from inception to June 2011
(Medline through PubMed andWeb of Science with conference
proceedings). See the supplementary file for details of the search
strategy. No language restrictions were applied. We screened
and cross checked identified systematic reviews and
meta-analyses evaluating ACE inhibitors or ARBs, as well as
reference lists of papers for potential additional studies. We also
searched the Food and Drug Administration website (10 June
2011) for regulatory documents with unpublished data from
clinical trials.
Study selection and data collection process
The titles and abstracts of obtained records were screened.
Doubts and disagreements were resolved by consensus. We
assessed the selected studies in full text to determine
appropriateness for inclusion. Two authors independently
extracted data on study design, location, period of study,
patients’ characteristics, drug use and how it was assessed,
primary outcomes, data of required outcomes, and adjustments
of estimates.
When studies presented different estimates on primary outcomes
according to the severity of pneumonia, we extracted for analysis
only those reporting the most severe cases. For the primary
outcome we considered drug withdrawals due to pneumonia
only when no other estimates were available. When more than
one risk estimate was available from several sources, we used
only the most precise or adjusted measures of association from
each report. Otherwise we used the crude odds ratio or derived
it from the raw data.
Two authors (DC and JA) independently analysed the quality
of reporting by using a qualitative classification according to
risk of bias (high, unclear, or low). For observational studies
we used a six item classification based on the meta-analysis of
observational studies in epidemiology,25 the quality assessment
tool for systematic reviews of observational studies,28 and
strengthening the reporting of observational studies in
epidemiology.29 This system was adapted from a previously
published systematic review30 31 and took into consideration the
participants (if any justification was given for the cohort and
the study reported appropriate inclusion and exclusion criteria),
intervention (if drug use was adequately assessed and not based
on self report), outcome (if pneumonia was assessed by clinical
examination, radiological methods, or database codes and not
based on self report), and outcome adjustments (for both age
and at least one of the following: smoker or pulmonary disease,
cardiovascular diseases or drug use or chronic kidney disease;
other adjustments). For randomised controlled trials we adapted
the Cochrane Collaboration’s tool for assessing risk of bias to
evaluate the quality of reporting: randomisation method,
allocation concealment, blinding of participants and staff,
blinding of outcome assessment, selective reporting (if
pneumonia was a prespecified outcome), and description of
withdrawals.32 From these tools we derived risk of bias graphs.
Statistical analysis
We used RevMan 5.1.4 software for statistical analysis (Nordic
Cochrane Centre, Cochrane Collaboration, 2011) and to derive
forest plots showing the results of individual studies and pooled
analysis.
We carried out three analyses. Firstly, we compared ACE
inhibitors and ARBs with each control group using random
effects meta-analysis weighted by the inverse variance method
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to estimate pooled odds ratios and 95% confidence intervals.
Heterogeneity was assessed with the I2 test, which measures the
percentage of total variation between studies due to
heterogeneity.33 We used the random effects model
independently of the existence (I2≥50%) of substantial
heterogeneity between the results of trials, as we pooled the
results of studies with different designs and patients’
characteristics. We chose the odds ratio as the measurement
estimate for effect because relative estimates are more similar
than absolute effects across studies with different designs,
populations, and lengths of follow-up.34 Raw data were first
converted to odds ratios through classic methods, or through
Peto’s method if one arm had a zero count cell. When raw data
or odds ratios were not available we took the hazard ratio or
risk ratio for analysis. To explore differences in estimates for
outcomes we presented the results stratified according to study
design. For the purpose of the analysis we treated nested
case-control studies as cohort studies. We carried out subgroup
analyses for patients with previous stroke, heart failure, and
chronic kidney disease because such patients are known to be
particularly susceptible to pneumonia and all indications are
clinically approved for treatment with ACE inhibitors and
ARBs.5 6 35 36 In view of the suggestion that ACE inhibitors may
be more efficient in reducing the risk of pneumonia in Asian
patients we also calculated estimates for Asian and non-Asian
populations.37 We evaluated differences between subgroups
with the method described by Deeks et al, based on the inverse
variance method.33
In the second analysis we carried out adjusted indirect
comparisons between the pooled estimate of ACE inhibitors
(versus control) and ARBs (versus control) using the Bucher
frequentist method, which compares different treatments
adjusted to the results of their direct comparison with a common
control.38 This method partially overcomes the problem of
different prognostic characteristics between participants among
studies, and it is believed to be valid assuming that the relative
effect of interventions is consistent across different studies, as
verified in our case.39 By default we used the random effects
model because adjusted indirect comparisons that used the fixed
effects model tend to underestimate the standard errors of pooled
estimates.39
Thirdly, we combined evidence generated by indirect
comparisons with evidence from head to head studies comparing
ACE inhibitors with ARBs using the random effects model for
quantitative pooling,40 41 and we determined the discrepancy
and heterogeneity between direct and indirect estimates.42
We also calculated the number needed to treat (NNT) and 95%
confidence intervals, taking into account the baseline risk
(weighted proportion of event rate in control group) because of
the differences in the predicted absolute benefit of treatment
according to variation in baseline risk between groups.34 43 In
our case, the weighted risk of pneumonia in the control groups
was 4.6% (95% confidence interval 3.1% to 6.7%). Publication
bias was assessed through visual inspection of the asymmetry
in funnel plots.
Results
The search of the electronic databases yielded 807 published
studies. After applying the inclusion and exclusion criteria 29
studies were included for analysis (fig 1⇓). The results from
eight additional studies were identified in the FDA regulatory
documents. Overall, data were obtained from 37 studies.20-22 44-79
Description of studies
The 37 studies included 18 randomised controlled trials,20 44-61
11 cohort studies,62-73 two nested case-control studies,21 74 and
six case-control studies.22 75-79
Among randomised controlled trials, eight were done
worldwide,47 48 51 52 55 57 58 61 six in Europe,44-46 53 56 60 three in
Asia,49 50 59, and one in Europe and the United States.54 Most of
the randomised controlled trials were multicentre (n=16). Seven
randomised controlled trials compared ACE inhibitors with
controls,44-50 nine compared ARBs with controls,51-59 and two
compared ACE inhibitors with ARBs.60 61 Seven trials reported
specific data for serious pneumonia, five for fatal pneumonia,
and eight reported pneumonia without specifying the severity
of disease. In only two trials was pneumonia a prespecified
outcome.49 59
Among observational studies, 10 were carried out in Asia, five
in the United States, and four in Europe. Eleven studies were
retrospective and eight were prospective. Seventeen evaluated
ACE inhibitors, two ARBs, and two compared ACE inhibitors
with ARBs.
Tables 1 to 3⇓⇓⇓ summarise the main characteristics of the
included studies.
The overall quality of the studies was considered to be good.
All the randomised controlled trials, except one,51met the criteria
for random sequence generation and about half specifically
reported adequate allocation concealment.46 48 50 54 55 57 58 61 Only
two randomised controlled trials56 59 were considered to be at
high risk of performance bias. Adequate blinding of outcome
assessment45-48 50 52-59 61 and full description of study
withdrawals44-55 57 58 60 61 were reported in 78% and 89% of
randomised controlled trials, respectively. The highest risk of
bias was found for potential reporting bias because only two
randomised controlled trials presented results for pneumonia
as a prespecified outcome.49 59 Supplementary figures 1 and 2
show the results of the quality appraisal of the randomised
controlled trials.
All observational studies were considered to have adequate
inclusion and exclusion criteria and provided justification for
the cohort. Five studies (26%)62-64 66 69 did not clearly stated how
the drug use was assessed, and four studies (21%)63 64 66 73 did
not provide details about outcome assessment. Eleven studies
(58%)21 22 68 70-72 74 75 77 79 provided results after adjustment for at
least one potential variable confounder. In one study76 it was
unclear for which variables the results were adjusted. Few
studies (26%) reported results adjusted for multiple confounders,
and in seven studies (37%) no type of adjustment was
mentioned. Supplementary figures 3 and 4 show the results for
the quality of the observational studies.
Primary outcome: incidence of pneumonia
Primary outcome data were available from 19 studies comparing
ACE inhibitors with controls (five randomised controlled trials,
eight cohort or nested case-control studies, and six case-control
studies), 11 studies comparing ARBs with controls (nine
randomised controlled trials and two cohort or nested
case-control studies), and two studies comparing ACE inhibitors
with ARBs (one randomised controlled trial and one cohort
study).
Use of ACE inhibitors was associated with a significant 34%
reduction in risk of pneumonia compared with controls (odds
ratio 0.66, 95% confidence interval 0.55 to 0.80; I2=79%). The
NNT for 2.0 years was 65 (48 to 112). The magnitude of the
risk reduction was similar across all study designs (P=0.78 for
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subgroup differences). The odds ratios for randomised controlled
trials, cohort or nested case-control studies, and case-control
studies were 0.69 (0.56 to 0.85; I2=0%), 0.58 (0.38 to 0.88;
I2=79%), and 0.67 (0.49 to 0.93; I2=73%), respectively (fig 2⇓).
The risk of pneumonia was not, however, different between
patients who did or did not use ARBs (0.95, 0.87 to 1.04;
I2=14%). Odds ratio estimates for randomised controlled trials
(0.90, 0.79 to 1.01; I2=7%) and cohort or nested case-control
studies (1.01, 0.94 to 1.09; I2=0%) did not differ significantly
(P=0.10; fig 3⇓).
Pooled results from the two head to head studies showed a
non-significant 37% reduction in risk of pneumonia associated
with use of ACE inhibitors (0.63, 0.28 to 1.44; I2=78%). In this
case, estimates from the randomised controlled trial and cohort
study differed significantly (P=0.03) (see supplementary figure
5).
Indirect comparison of ACE inhibitors with ARBs showed a
significant 30% reduction in risk of pneumonia associated with
use of ACE inhibitors (0.70, 0.56 to 0.86). Similar results were
obtained from pooled direct and indirect estimates (0.69, 0.56
to 0.85) without discrepancy (P=0.82) or heterogeneity (I2=0%)
between both estimates (fig 4⇓). The NNT for 2.2 years based
on this estimate was 72 (51 to 147).
Subgroup analyses for primary outcome
Patients with previous stroke
In patients with previous stroke, use of ACE inhibitors was
associated with a 54% reduction in risk of pneumonia compared
with controls (0.46, 0.34 to 0.62, I2=0%; seven studies pooled)
(see supplementary figure 6). In the same population, however,
use of ARBs was not associated with a significant reduction in
risk (0.86, 0.67 to 1.09; I2=0%; two studies pooled) (see
supplementary figure 7).
The pooled estimate from indirect (odds ratio 0.53, 95%
confidence interval 0.16 to 1.79) and direct (0.38, 0.17 to 0.81)
evidence of ACE inhibitors compared with ARBs showed a
significant 58% reduction in risk of pneumonia (0.42, 0.22 to
0.80; fig 4), without discrepancy (P=0.44) or heterogeneity
(I2=0%) between indirect and direct estimates.
Patients with heart failure
In patients with heart failure, two studies evaluated the risk of
pneumonia in those treated with ACE inhibitors44 45 and two
other studies reported data for those treated with ARBs.51 52ACE
inhibitors were associated with a significant 37% reduction in
risk of pneumonia (0.63, 0.47 to 0.84; I2=0%), whereas ARBs
showed no significant effect (0.85, 0.49 to 1.47; I2=15%) (see
supplementary figure 8).
Patients with chronic kidney disease
In patients with chronic kidney disease, the results from one
randomised controlled trial of ACE inhibitors46 (odds ratio 0.15,
95% confidence interval 0.00 to 7.70) and two randomised
controlled trials of ARBs52 53 (1.21, 0.32 to 4.52; I2=77%) did
not differ significantly when compared with controls (see
supplementary figure 9).
Asian and non-Asian patients
Eleven studies were carried out in Asian countries and 11 were
done outside of Asia. The PROGRESS20 study was the only
multicentre study carried out worldwide that supplied separate
data for Asian and non-Asian patients. To lower analysis bias,
the other studies carried out worldwide that did not provide
separate data for both groups were excluded.
The reduction in risk of pneumonia associated with ACE
inhibitors was significantly higher among Asian patients (0.43,
0.34 to 0.54; I2=0%) compared with non-Asian patients (0.82,
0.67 to 1.00, I2=80%, P<0.001 for subgroup differences) (see
supplementary figure 10). ARBs, however, were not associated
with a reduction in risk of pneumonia in Asian patients (1.04,
0.59 to 1.84; one randomised controlled trial HIJ-CREATE59)
or non-Asian patients (0.97, 0.84 to 1.12; I2=27%; five studies
pooled; fig 4 and supplementary figure 11).
Secondary outcome: pneumonia related
mortality
Data for secondary outcomes were extracted from seven studies
comparing ACE inhibitors with controls (three randomised
controlled trials and four cohort studies),20 49 50 68 70-72 one
randomised controlled trial comparing ARBs with control,55 and
one head to head randomised controlled trial.60 Five studies
comparing ACE inhibitors with controls were carried out on an
enriched population—that is, enrolled patients with
pneumonia.49 68 70-72
Treatment with ACE inhibitors was associated with a significant
27% reduction in risk of pneumonia related mortality compared
with controls (0.73, 0.58 to 0.92; I2=51%), without significant
differences between estimates from randomised controlled trials
and observational studies (P=0.76). The pooled result from
randomised controlled trials, however, failed to reach statistical
significance (0.61, 0.20 to 1.90; I2=61%) (fig 5⇓).
Only one randomised controlled trial55 reported the effect of
treatment with ARBs on pneumonia related mortality (odds
ratio 0.63, 95% confidence interval 0.40 to 1.00) (fig 5).
The risk of pneumonia related mortality in indirect (1.16, 0.69
to 1.94), direct (HEAVEN randomised controlled trial60 7.29,
0.14 to 367.24), and pooled comparisons (1.19, 0.71 to 1.98)
did not differ between ACE inhibitors and ARBs (fig 4). There
was no discrepancy (P=0.36) or heterogeneity (I2=0%) between
indirect and direct estimates.
Publication bias
Visual inspection of funnel plots did not reveal any obvious
asymmetrical tail (see supplementary figure 12). Publication
bias was not suggested by sensitivity analysis taking into account
published and unpublished trials (see supplementary figure 13).
Discussion
In this systematic review we found that treatment with
angiotensin converting enzyme (ACE) inhibitors was associated
with a significant reduction in risk of pneumonia compared with
control treatment and angiotensin receptor blockers (ARBs);
the magnitude of this reduction (about one third) was similar
across studies with different designs (randomised controlled
trials, cohort, and case-control studies). The risk of pneumonia
was also reduced in patients treated with ACE inhibitors who
were at higher risk of pneumonia, in particular those with stroke
and heart failure. Most of the potential protective benefit from
ACE inhibitors seemed to be in Asian patients; it is unclear
whether the methodology of the studies or the clinical and
genetic characteristics of the patients were responsible for this
finding. Use of ACE inhibitors was also associated with a
reduction in pneumonia related mortality, although the results
were less robust than for overall risk of pneumonia; it is
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uncertain if differences exist between ACE inhibitors and ARBs
for this outcome.
The present review was designed to determine the effect of
treatment with ACE inhibitors and ARBs on risk of pneumonia.
We combined data from both experimental and observational
studies to obtain more robust results, mainly because no
randomised controlled trial was primarily designed with this
objective. Pneumonia is not a rare outcome (particularly in
populations treated with ACE inhibitors or ARBs) or an outcome
that only occurs months to years after use of ACE inhibitors or
ARBs. Therefore randomised controlled trials would have been
an appropriate study design to deal with this problem.We found
significant statistical heterogeneity for ACE inhibitors but not
for ARB results. This was due to the results of observational
studies (no heterogeneity was found among randomised
controlled trials). Nevertheless, the observed statistical
heterogeneity was more quantitative than qualitative because
all estimates for study designs share the same direction. This
consistency, as well as the robustness of reduction in the risk
of pneumonia across all study designs, suggests that use of ACE
inhibitors deserves attention. Furthermore, that ACE inhibitors
reduced the risk of pneumonia compared not only with the
control group but also with ARB treatment, is reassuring because
patients’ characteristics and risk factors, as well as other
potential clinical andmethodological confounders are probably
similar between studies on ARBs and those on ACE inhibitors.
We were also conservative in our analysis because we did not
consider undefined data or data on upper respiratory tract
infections, and when studies presented different estimates
according to the severity of pneumonia we extracted those
reporting only the most severe cases and the most precise or
adjusted measure.
Our findings have potential clinical implications. ACE inhibitors
are widely prescribed and prescriptions may be influenced by
concerns about potential adverse effects, in particular cough,
which may be protective. The incidence of ACE inhibitor
induced cough has been reported to be in the range of 5% to
35%.80 Our results suggest that patients taking ACE inhibitors
who develop cough should, providing that cough is tolerable,
persist with treatment. Compliance and persistence with
treatment is important. Furthermore, from an evidence based
perspective, there is little to choose between ACE inhibitors
and the more expensive ARBs. However, in the case of a
particular patient, in whom ACE inhibitors and ARBs are
presumed to have similar clinical benefit, our results may also
influence the choice of prescription in those at high risk of
pneumonia. Therefore patients with risk factors for pneumonia
andmorbidities that require treatment with ACE inhibitors may
have an additional reason to continue treatment.
A further important aspect of our results was the reduction in
risk of pneumonia across high risk patients, which provided
consistency to the overall results. Patients with previous stroke
have increased susceptibility to pneumonia owing to risk of
aspiration associated with decreased protective reflexes of the
respiratory system mediated by substance P and post-stroke
dysphagia.14 81 About 20% of these patients will develop
pneumonia,82which is a predictor of poor functional outcome83 84
and a relevant cause of death.84 85 The putative protective effect
of ACE inhibitors in this population was predictable given the
importance of dysphagia and substance P in these patients.
According to one study, ARBs do not increase the levels of
substance P or improve asymptomatic dysphagia.86 This
highlights the importance of using ACE inhibitors in patients
with previous stroke who have comorbidities for which ACE
inhibitors are recommended.
Only a few studies evaluated other populations with increased
risk, such as patients with heart failure or chronic kidney disease.
For patients with heart failure, the decreased risk of pneumonia
was also found in patients treated with ACE inhibitors. The
suggested effect was significant but this evaluation lacked robust
data. ARBs did not show any protective effect.
The putative preventive effect of ACE inhibitors on pneumonia
in Asian patients has been suggested.37 We explored this
subgroup and compared the effect with non-Asian patients.
Furthermore, we obtained a considerable weight of evidence
from studies that evaluated Asian patients. ACE inhibitors
significantly reduced the risk of pneumonia in both Asian and
non-Asian patients, although the odds reduction was
significantly higher in Asian patients (57% v 12%; P<0.001).
ARBs did not reduce the risk of pneumonia in either population.
Genetic differences in ACE polymorphisms between Asian and
non-Asian patients have been suggested to explain the difference
in protective effects. Polymorphisms I/I and I/D, which are more
prevalent in Asian population, showed a protective trend in the
post-hoc analysis in PROGRESS, whereas the D/D
polymorphismwas less protective.20 77 87 This last polymorphism
is associated with acute respiratory distress syndrome,
particularly in white populations.88 This potential loss of
protective effect may be explained by increased levels of serum
ACE inhibitors and catabolism of kinins in patients with the
D/D polymorphism.89 However, genetic evidence is equivocal.
One study did not find an association between any specific
genotype and pneumonia.90 Other factors should be explored to
explain these differences in ethnic groups or by geographical
location to better define those who can benefit more.
Our conclusions are weaker for pneumonia related mortality
because fewer studies provided data for this outcome and
significant heterogeneity existed for the results of ACE
inhibitors. This uncertainty was reflected by the wider
confidence intervals. Treatment with ACE inhibitors (three
randomised controlled trials and four cohort studies) and ARBs
(one randomised controlled trial) were both associated with a
decreased risk of pneumonia related mortality. Explanations for
such findings may rely on modulation of cardiovascular risk by
ACE inhibitors and ARBs because deaths due to cardiovascular
disease are not uncommon among patients with pneumonia.27 91
Decreased mortality may also be explained by the role of ACE
inhibitors in pulmonary injury and production of cytokines,
which may be related to severity of pneumonia.92-94 ACE
inhibitors may influence the pattern for release of cytokines
exerting anti-inflammatory effects that could reduce the severity
of and mortality from pneumonia.95
The influence of ACE inhibitors on survival in these patients
should be interpreted carefully because observational studies
with enriched populations accounted for most of the weight of
the pooled analysis, whereas meta-analysis of three randomised
controlled trials (one with an enriched population) did not show
differences between ACE inhibitors and controls. However,
there was no significant difference in effects between overall
randomised controlled trials and observational studies. Although
the data were not robust, they did suggest that the effects of
treatment with ACE inhibitors on mortality were mostly
noticeable in patients with pneumonia.
Limitations of the review
The results and conclusion of this review are weakened by
limitations inherent to meta-analysis and individual studies. The
overall quality of included studies was good. However, reporting
quality for a few studies, particularly observational ones, was
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low as some of these were abstracted from character limited
sections such as letters or comments.
The higher risk of bias was found for potential selective
reporting in randomised controlled trials and presentation of
unadjusted risk estimates in observational studies. Both limit
the strength of our conclusions. A key limitation is that not one
randomised controlled trial was primarily designed to assess
the effects of ACE inhibitors or ARBs on pneumonia. Although
we searched a large number of studies, only a few reported this
outcome. Among these, only two randomised controlled trials
(<25%) had pneumonia or pneumonia related mortality as a
predefined outcome.49 59 As a consequence we were able to
extract data only from studies where authors considered
pneumonia to be an important outcome, because of either
scientific interest or statistical significance.
Observational studies had an important weight in the results for
the primary outcome and this should be taken into account when
interpreting the clinical implications of our findings. Use of
cardiovascular drugs in observational studies could bias results,
because patients using drugs could be more concerned for their
health and more willing to followmedical advice than controls,
the so-called healthy user effect bias.96 However, patients with
pneumonia are likely to have a higher risk of cardiovascular
disease91 97 and are more likely to be treated with ACE inhibitors,
counterbalancing the bias from a healthy user effect.
Additionally, the magnitude of the odds risk reduction was
similar for randomised controlled trials, cohort studies, and
case-control studies.
Pooling data from studies with different designs (confounding
bias in observational studies) that evaluated patients in different
settings (community based and hospital based studies; referral
bias), as well as with different baseline morbidities and
heterogeneous risk (membership bias) for pneumonia, should
also be taken into account as limitations to our conclusions. The
degree of statistical heterogeneity was in fact high in some
comparisons. Nevertheless, the pooled estimates from
experimental and observational studies were similar. In this
case, pooling experimental and observational data increased the
power and external validity of the findings.
Included studies compared different ACE inhibitors and ARBs
with different controls, such as placebo, calcium channel
blockers, and β blockers. In the present analysis we did not carry
out serial subgroup analysis to explore if the effect was different
for a particular drug because of the scarcity of the data and the
risk of obtaining a result by chance.
Finally, we used adjusted indirect comparisons to estimate the
effect of ACE inhibitors compared with ARBs. Although
combined indirect and direct evidence showed no discrepancies
or heterogeneity, the results should not be thought as definitive
conclusions because of the possibility of imbalanced data from
studies with different designs, baseline risk of patients, and
length of follow-up.
Conclusions
Our results suggest an important role of ACE inhibitors, but not
ARBs, in reducing the risk of pneumonia. These data may
discourage the withdrawal of ACE inhibitors in some patients
with tolerable adverse events (namely, cough) who are at
particularly high risk of pneumonia. Specific designed
randomised controlled trials are required to establish definite
conclusions and to estimate better the true magnitude of this
putative protective effect. Patients with previous stroke and
Asian patients are patient populations that could benefit more
from treatment with ACE inhibitors. ACE inhibitors also
lowered the risk of pneumonia related mortality, mainly in
patients with established disease, but the robustness of the
evidence was weaker.
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Tables
Table 1| Main characteristics of randomised controlled trials included in review
Data*
Outcomes
abstracted
Primary
outcome
Mean
(SD)
ageNo (total)ComparisonPatients
Mean
follow-up
(years)LocationStudy
ACE inhibitors
v control:
PublishedSerious pneumonia†Assessment of
changes in
exercise
tolerance
57.5
(10)
200 v 48
(248)
Spirapril or enalapril v placeboPatients with
chronic congestive
heart failure
0.2Multicentre
Czech
Republic
and
Slovakia
CASSIS
199544
PublishedPneumonia†Death from any
cause
67.5876 v 873
(1749)
Trandolapril v placeboPatients with left
ventricular ejection
fraction after
myocardial
infarction
4.0Multicentre
Denmark
TRACE 199545
PublishedDrug withdrawal due
to
bronchopneumonia†
Rate of decline
in glomerular
filtration
49.3
(13.6)
78 v 88
(166)
Ramipril v placeboPatients with
chronic
nephropathy and
persistent
proteinuria
1.3Multicentre
Italy
GISEN 199746
UnpublishedSerious pneumonia†Myocardial
infarction,
stroke, or death
due to
cardiovascular
disease
66 (7)4645 v 4652
(9297)
Ramipril v placeboPatients at high
risk of developing
a major
cardiovascular
event
4.0Multicentre
worldwide
(not Asia)
HOPE 200047
PublishedFatal and non-fatal
pneumonia
Fatal or
non-fatal stroke
64
(10)
3051 v 3054
(6105)
Perindopril v placeboPatients with
previous stroke or
transient
ischaemic attack
3.9Multicentre
worldwide
PROGRESS
200420 48
PublishedHospital deathIn-hospital
mortality,
duration of
antibiotic use,
and infection
with MRSA
78 (8)33 v 35 (68)Imidapril+amantadine+standard
care v standard care
Patients aged ≥65
with history of
stroke and
admitted with
community
acquired
pneumonia
4.0Single
centre
Japan
Kanda 200449
PublishedPneumonia as cause
of mortality
Composite of
doubling of
serum creatinine
level, end stage
renal disease,
and death
44.8
(14.6)
216 v112
(328)
Benazepril v placeboPatients with
non-diabetic
chronic kidney
disease
3.4Single
centre
China
Hou 200650
ARBs v control:
PublishedPneumonia†Adverse events54125 v 29Losartan v placeboPatients with
essential
hypertension and
heart failure
0.3WorldwideWeber 199751
UnpublishedPulmonary infection†Time to first
occurrence of
doubling of
baseline serum
creatinine level,
end stage renal
58.9
(7.8)
579 v 569
(placebo)
(1148)
Irbesartan v placebo or
amlodipine
Patients with
hypertension and
with type 2
diabetes and overt
proteinuria
4.8Multicentre
worldwide
IDNT 200152
disease, or
death
UnpublishedPulmonary infection†Time to
occurrence of
clinical overt
albuminuria
58.0
(8.1)
389 v 201
(590)
Irbesartan 100 mg v irbesartan
300 mg v placebo
Patients with
hypertension and
with type 2
diabetes,
microalbuminuria,
and normal renal
function
2.0Multicentre
Europe
IRMA-2 200153
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Table 1 (continued)
Data*
Outcomes
abstracted
Primary
outcome
Mean
(SD)
ageNo (total)ComparisonPatients
Mean
follow-up
(years)LocationStudy
Published
and
unpublished
Pneumonia and
serious pneumonia†
Morbidity and
mortality due to
cardiovascular
disease
66.9
(7.0)
4605 v 4588
(9193)
Losartan v atenololPatients with
essential
hypertension and
signs of left
4.8Multicentre
Europe
and USA
LIFE 200254
ventricular
hypertrophy on
electrocardiogram
UnpublishedSerious pneumonia
and death due to
pneumonia†
All cause
mortality
66.6
(10.7)
3803 v 3796
(7599)
Candesartan v placeboPatients with
symptomatic heart
failure and
reduced or
preserved left
ventricular ejection
fraction
3.1Multicentre
worldwide
CHARM
200355
PublishedPneumonia†Total mortality
and all
cardiovascular
and
cerebrovascular
events
67.9
(10)
681 v 671
(1352)
Eprosartan v nitrendipineHigh risk patients
with hypertension
and with cerebral
event during past
24 months
2.5Multicentre
Germany
and Austria
MOSES
200556
UnpublishedSerious pneumonia†Composite
endpoint
consisting of
death due to
cardiovascular
disease,
66.9
(7.4)
2954 v 2972
(5926)
Telmisartan v placeboPatients with high
risk of developing
a cardiovascular
event and who
were intolerant to
ACE inhibitors
4.8Multicentre
worldwide
TRANSCEND
200857
non-fatal
myocardial
infarction,
non-fatal stroke,
and admission
to hospital for
congestive heart
failure
UnpublishedSerious pneumonia†Time to first
recurrent stroke
66.2
(8.6)
5589 v 5277
(10866)
Telmisartan v placeboPatients with
recent ischaemic
stroke without
treatment with
ACE inhibitors
2.0Multicentre
worldwide
PRoFESS
200858
PublishedPneumonia†Time to first
major adverse
cardiovascular
event
65 (9)1024 v 1025
(2049)
Candesartan v non-ARBPatients admitted
to hospital with
coronary artery
disease and
hypertension
between 20 and
80 years old
4.2Multicentre
Japan
HIJ-CREATE
200959
ACE inhibitors
v ARBs:
PublishedDeath due to
pneumonia
Exercise
capacity
measured as
distance walked
during six
minute walk test
6871 v 70
(141)
Enalapril v valsartanPatients with
stable mild or
moderate heart
failure and systolic
dysfunction
0.2SwedenHEAVEN
200260
UnpublishedSerious pneumonia†Time to first
occurrence of
either death due
cardiovascular
disease,
myocardial
66.48576
(ramipril) v
8542
(telmisartan)
(17118)
Ramipril v telmisartan v
telmisartan+ramipril
Patients at high
risk of developing
major
cardiovascular
event
4.6Multicentre
worldwide
ONTARGET
200861
infarction,
stroke, or
admission to
hospital for
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Table 1 (continued)
Data*
Outcomes
abstracted
Primary
outcome
Mean
(SD)
ageNo (total)ComparisonPatients
Mean
follow-up
(years)LocationStudy
congestive heart
failure
ACE=angiotensin converting enzyme; ARB=angiotensin receptor blocker; MRSA=meticillin resistant Staphylococcus aureus.
*Data for unpublished articles were obtained from FDA regulatory documents.
†Adverse event.
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Table 2| Main characteristics of cohort studies included in review
Outcome
adjustments
Ascertainment
Outcome
measures
Mean
(SD)
age
No
(total)ComparisonPatients
Data source;
period of
study
Study
length
(years)
Location,
study
designStudy OutcomesDrug use
for
confounders
NRNRNRPneumonia77 (8)127 v
313
(440)
Imidapril,
enalapril or
captopril v
CCB or β
blocker
Patients with
stroke treated
with
hypertensive
drugs
March 1996-982.5Japan,
prospective
(patients in
long term
facilities)
Sekizawa
199862
NRNRNRPneumoniaNR234
(ACE
inhibitor)
v 264
(CCB)
(498)
ACE inhibitor
v CCB v ACE
inhibitor+CCB
Outpatients
with
hypertension
1995-984.0Japan,
retrospective
Teramoto
199963
NRNRNRPneumonia75.9466 v
413
(879)
Imidapril v
CCB
Elderly patients
with
hypertension
January
1995-December
1999
4.0Japan,
prospective
Arai 200064
and Arai
199865
NRNRNRPneumoniaNR209 v
195
(404)
ACE inhibitor
v ARB
Elderly patients
with
hypertension
and stroke
January
1998-May 2002
2.0Japan,
prospective
Arai 200166
NRNRNRPneumonia75 (1)430 v
409 v
351 v
160
(1350)
ACE inhibitor
v CCB v
diuretics v
control
Patients with
stroke who
were not
bedridden and
were followed
for >6 months
after stroke
April 1999-20023.0Japan,
prospective
Arai 200567
Pneumonia
severity and
history of
hypertension
and diabetes
mellitus
ICD-9 codesSelf reporting
and
electronic
medical
records
30 day
mortality
60
(16)
194 v
593
(787)
ACE inhibitor
v control
Patients with
primary
discharge
diagnosis of
pneumonia or
secondary
Texas
Department of
Health and
Department of
Veteran Affairs
clinical
4.0USA,
retrospective
(hospital
based
cohort)
Mortensen
200568
dischargedatabase;
diagnosis ofJanuary
pneumoniawith1999-December
2002 primary
diagnosis of
respiratory
failure or sepsis
NRNRNRPneumonia68 (2)22 v 61
(83)
ACE inhibitor
v control
Elderly patients
admitted to
hospital with
intracerebral
haemorrhage
2 years2.0Japan,
prospective
Harada
200669
Age, sex,
marital status,
classes of
drugs, and
Charlson
composite
score
Pharmacy
data from
Pharmacy
Benefits
Management
group
databases
Assessed
from
beneficiary
identification
records
locator
subsystem
30 day
mortality
75.2
(6.1)
2930 v
5722
(8652)
ACE inhibitor
v control
Elderly patients
admitted to
hospital with
community
acquired
pneumonia
National patient
care database
from Austin
Automation
Center; July
1999-January
2000
1 yearUSA,
retrospective
Mortensen
200870
and national
patient care
database
Age,
pneumonia
severity,
comorbidity,
smoking
status, and
NRSelf report of
drugs
confirmed
with general
practitioner
after
admission
30 day
mortality
66136/31 v
871
(1038)
ACE inhibitor
or ARB v
control
Patients with
community
acquired
pneumonia
NHS Lothian
University
Hospitals
Division January
2005-November
2007
3 yearsUK,
prospective
(community
based
cohort)
Chalmers
200871
other
cardiovascular
drugs
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Table 2 (continued)
Outcome
adjustments
for
confounders
Ascertainment
Outcome
measures
Mean
(SD)
age
No
(total)ComparisonPatients
Data source;
period of
study
Study
length
(years)
Location,
study
designStudy OutcomesDrug use
Age, sex,
Townsend
ICD-9 codesData
extracted
30 day
mortality
>40795 v
2886
(3681)
ACE inhibitor
v control
Patients with
pneumonia
The Health
Improvement
Network
2.8UK,
retrospective
(population
Myles
200972
deprivationfrom all
database; July
2001-July 2005
based
cohort)
score, current
smoking,
recorded
prescriptions
Charlsonwithin 30
comorbiditydays from
index, andpneumonia
index date other use of
drugs
NRNRNRPneumonia>60147 v
342
(489)
ACE inhibitor
v control
Patients with
hypertension
and stroke
NRNRChina,
prospective
Cuifang
201073
CCB=calcium channel blockers; ACE=angiotensin converting enzyme; ARB=angiotensin receptor blocker; NR=not reported.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e4260 doi: 10.1136/bmj.e4260 (Published 11 July 2012) Page 13 of 20
RESEARCH
Table 3| Main characteristics of case-control studies included in review
Outcome
adjustments
Ascertainment
Outcome
Mean
(SD)
age
No with
pneumonia
v controls
(total)
ACE
inhibitor
or ARBMatchingPatients
Data source;
period of study
Data
length
(years)
Location,
study designStudy OutcomeDrug use
Nested
case-control
studies:
Sex, comorbidities,
previous heart
failure, number of
physician visits,
and drugs used
ICD-9 codesDatabase
records
Admitted to
hospital
with
pneumonia
71
(8.3)
1666 v 33315
(47 148)
NRRatio 1:20;
time of
follow-up,
same
calendar
year of
Patients who
went for coronary
revascularisation
procedure and
had incident
pneumonia after
Databases of
administrative
healthcare
programmes
offered to
residents of
5.0Canada,
retrospective
Etminan
200621
cohorthospital
discharge
Quebec;
1996-2000 entry, and
age
Diabetes,
inflammatory
diseases,
cardiovascular
diseases, chronic
kidney disease,
ICD-9 codesRecords of
filled
pharmacy
claims
Pneumonia58.2
(12.7)
7429 v 73571
(81 000)
NRRatio 1:10;
age, sex,
residence,
insurance
plan,
subscriber
Patients with
hypertension and
incident
pneumonia
Data on adults
with hypertension
insured by large
commercial plans;
January
2000-November
2007
7.0USA, Puerto
Rico, and US
Virgin Islands,
retrospective
Mukamal
201074
organstatus, and
transplantation,
and drugs used
date of
enrolment
Case-control
studies:
Age, sex,
dementia,
hypoalbuminemia,
bedridden state,
lung disease, and
antacid use
Personal
physicians.
Questionable
events
reviewed by
physician
Hospital
computerised
pharmacy
database
Admission
for
pneumonia
81.1
(7.7)
55 v 220
(275)
Temocapril,
alacepril,
cilazapril,
captopril
Ratio 1:4;
sex and
age
Patients aged
≥65 years with
fatal or non-fatal
pneumonia
Department of
Internal Medicine
of
Hanwa-Senbooku
Hospital; July
1996-June 1997
1.0Japan,
prospective18
(hospital-based
study)
Okaishi
199975
blinded to
patients’
drugs
Multivariate, not
defined
Database
records
Database
records
Hospital
admission
for
pneumonia
78.5
(8.2)
204 v 204
(408)
NRRatio 1:1;
age,
admission
date, and
residence
Patients aged
>65 years
readmitted to
hospital with
pneumonia over
1 year from first
episode
Electronic
database from 3
tertiary care
hospitals; March
1999-August 2003
4.0USA,
retrospective
El Solh
200476
Age, sex,
bedridden state,
congestive heart
failure, diabetes
mellitus, lung
disease, ACE
Information
collected by
full time
nurses under
physicians’
supervision.
Hospital
computerised
pharmacy
database
Pneumonia82.8
(8)
105 v 420
(525)
TemocaprilRatio 1:4;
sex and
age
Patients with
admission period
>3 months who
presented with
fatal or non-fatal
pneumonia
April
1999-November
1999
0.7Japan,
retrospective
(hospital based
study)
Takahashi
200577
polymorphism, andQuestionable
use of other
antihypertensives
events were
reviewed by
physician
without
knowledge of
patients’
drugs
Diabetes,
respiratory
diseases, heart
failure, use of
systemic
corticosteroids,
ICD-9 codesATC
classification
Hospital
admission
for
community
acquired
pneumonia
67
(0.51)
1108 v 3817
(4925)
NRRatio 1:4;
age and
sex
Patients admitted
to hospital with
primary diagnosis
of pneumonia
PHARMO record
linkage system
and PRISMANT
records; January
1995-December
2000
6.0Netherlands,
retrospective
(population
based study)
Van de
Garde 200622
and use of gastric
acid suppressants
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Table 3 (continued)
Outcome
adjustments
Ascertainment
Outcome
Mean
(SD)
age
No with
pneumonia
v controls
(total)
ACE
inhibitor
or ARBMatchingPatients
Data source;
period of study
Data
length
(years)
Location,
study designStudy OutcomeDrug use
Age, congestive
heart failure,
Codes of
Oxford
Receipt of
prescriptions
Pneumonia73
(11)
4719 v 15
332 (20 041)
Cilazapril,
captopril,
Ratio 1:4;
age, sex,
Patients with
diabetes who had
UK General
Practice Research
14.0UK,
retrospective
Van de
Garde 200778
history of stroke,Medicalwithin yearenalapril,type offirst diagnosis of
pneumonia
Database; June
1987-January
2001
evident alcohol
misuse, pulmonary
Information
System
before index
date
fosinopril,
lisinopril,
stroke, NIH
Stroke
diseases, smoking,perindopril,Scale
number of generalquinapril,score, side
practitioner visits aramipril,
trandolapril
and depth
of stroke year, oral
glucocorticoid use,
statin use,
pneumococcal
vaccination, and
use of gastric acid
suppressants
Presence of
tracheostomy or
feeding tube
Medical
records,
chest
radiography
confirmation
Medical
records
Pneumonia66.3
(12.1)
36 v 36 (72)NRNRPatients admitted
for inpatient
rehabilitation
within 90 days
after stroke onset
who developed
pneumonia
Stroke
rehabilitation
registry database,
September
1999-August 2003
4.0USA,
retrospective
Marciniak
200979
ACE=angiotensin converting enzyme; ARB=angiotensin receptor blocker; NR=not reported; ATC=anatomical therapeutic chemical system.
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Figures
Fig 1 Flow of studies through review. ACE=angiotensin converting enzyme; ARBs=angiotensin receptor blockers
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Fig 2 Risk of pneumonia with use of angiotensin converting enzyme (ACE) inhibitors compared with control treatment
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Fig 3 Risk of pneumonia with use of angiotensin receptor blockers (ARBs) compared with control treatment
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Fig 4Summary of meta-analysis estimates and subgroup analyses. ACE=angiotensin converting enzyme; ARBs=angiotensin
receptor blockers
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Fig 5 Pneumonia related mortality in studies comparing angiotensin converting enzyme (ACE) inhibitors or angiotensin
receptor blockers (ARBs) with control treatment
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